A- A A+

Methamphetamine-type stimulant use in Lao PDR: qualitative findings from users aged 15–25 years in Vientiane Capital and Vientiane Province

Vanphanom Sychareun, Bangone Santavasy, Niramonh Chanlivong, Andrea Fischer, Nicholas Thomson, Robert Power and Jo Durham

Harm Reduction Journal2018, 15:17, doi.org/10.1186/s12954-018-0222-1


Potential Psychiatric Uses for MDMA.

Yazar-Klosinski, B. and Mithoefer, M. (2017),

Clin. Pharmacol. Ther., 101: 194-196. doi:10.1002/cpt.565


Australien. Cracks in the Ice smartphone app provides more Australians with information about crystal methamphetamine (ice)

A smartphone app developed by researchers from the National Drug and Alcohol Research Centre (NDARC) at UNSW and National Drug Research Institute (NDRI) at Curtin University will allow more Australians to access trusted, evidence-based information and resources about crystal methamphetamine (ice). (NDARC/UNSW, 09.01.2018)


Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.

Schottenfeld RS, Chawarski MC, Sofuoglu M, Chooi WT, Zaharim NM, M Yasin MA, Ahmad I, Syed Jaapar SZ, Vicknasingam BK.

Drug Alcohol Depend. 2018 Mar 10;186:130-137. doi: 10.1016/j.drugalcdep.2018.01.017.



Treatment of methamphetamine addicts in the clinical practice in Germany

Katharina Schoett, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/7582/14H30_4_Katharina Schoett.pptx

mCPP: an undesired addition to the ecstasy market

MG BossongTM BruntJP Van DijkSM RigterJ. HoekHMJ GoldschmidtRJM Niesink

Journal of Psychopharmacology, Vol 24, Issue 9, pp. 1395 – 1401, doi.org/10.1177/0269881109102541


Social cognition and interaction in chronic users of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy").

Wunderli MD, Vonmoos M, Treichler L, Zeller C, Dziobek I, Kraemer T, Baumgartner MR, Seifritz E, Quednow BB.

Int J Neuropsychopharmacol. 2017 Oct 26. doi: 10.1093/ijnp/pyx098.


The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Faraone SV.

Neurosci Biobehav Rev. 2018 Feb 8;87:255-270. doi: 10.1016/j.neubiorev.2018.02.001.


Leidet die Empathiefähigkeit bei häufigem Ecstasykonsum?

Ecstasy kann das Bedürfnis verstärken, anderen Menschen nahe zu sein. Doch wie wirkt sich häufiger Ecstasy-Konsum langfristig auf die Empathiefähigkeit aus? Eine Studie aus der Schweiz hat Ecstasykonsumierende hierzu gründlich durchgecheckt. (drugcom.de, 24.11.2017)


Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies.

Kuypers KP, Dolder PC, Ramaekers JG, Liechti ME.

J Psychopharmacol. 2017 May;31(5):589-598. doi: 10.1177/0269881117699617.


After 16 years of preliminary clinical trials, the Food and Drug Administration (FDA) in late August gave expedited approval for multiple phase 3 trials of 3,4-methylenedioxymethamphetamine (MDMA) as a potential “breakthrough therapy” for treatment of posttraumatic stress disorder (PTSD). (American Psychiatric Association, 20.10.2017)


Methamphetamine dependence in methadone treatment services in Iran: the first literature review of a new health concern.

Alammehrjerdi Z, Ezard N, Dolan K.

Asian J Psychiatr. 2018 Jan 6;31:49-55. doi: 10.1016/j.ajp.2018.01.001.



One of the main targets in the war on drugs could well become a drug to treat the scars of war. The U.S. Food and Drug Administration (FDA) has designated 3,4-methylenedioxymethamphetamine (MDMA), better known as the illegal drug ecstasy, a "breakthrough therapy" for posttraumatic stress disorder (PTSD), a status that may lead to faster approval.

The agency has also approved the design for two phase III studies of MDMA for PTSD that would be funded by the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit in Santa Cruz, California. MAPS announced the "breakthrough therapy" designation, made by FDA on 16 August, on its website today; if the group can find the money for the trials, which together could cost an estimated $25 million, they may start next spring and finish by 2021. (Science, 26.08.2017)


Opioids and methamphetamine: a tale of two crises

The Lancet , Volume 391 , Issue 10122 , 713


Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder.

Najib J, Wimer D, Zeng J, Lam KW, Romanyak N, Paige Morgan E, Thadavila A.

J Cent Nerv Syst Dis. 2017 Aug 23;9:1179573517728090. doi: 10.1177/1179573517728090.


USA. Meth, the Forgotten Killer, Is Back. And It’s Everywhere.

PORTLAND, Ore. — They huddled against the biting wind, pacing from one corner to another hoping to score heroin or pills. But a different drug was far more likely to be on offer outside the train station downtown, where homeless drug users live in tents pitched on the sidewalk.

“Everybody has meth around here — everybody,” said Sean, a 27-year-old heroin user who hangs out downtown and gave only his first name. “It’s the easiest to find.”

The scourge of crystal meth, with its exploding labs and ruinous effect on teeth and skin, has been all but forgotten amid national concern over the opioid crisis. But 12 years after Congress took aggressive action to curtail it, meth has returned with a vengeance. Here in Oregon, meth-related deaths vastly outnumber those from heroin. At the United States border, agents are seizing 10 to 20 times the amounts they did a decade ago. Methamphetamine, experts say, has never been purer, cheaper or more lethal. (New York Times, 13.02.2018)


Breakthrough Therapy Designation ensures that FDA will work closely with MAPS to complete Phase 3 trials as efficiently as possible

MAPS and FDA have also reached agreement on design, primary endpoint, and statistical approach for Phase 3 trials

Posttraumatic stress disorder (PTSD) is a serious and life-threatening psychiatric condition with unmet medical need despite available treatments

MAPS is sponsoring two Phase 3 clinical trials of MDMA-assisted psychotherapy in patients with severe PTSD starting in 2018

MAPS, a non-profit research organization, has raised or pledged half of the $25 million estimated cost of these trials, with $12.5 million still needed. (MAPS - Multidisciplinary Association for Psychedelic Studies, 26.08.2017)


Konsum von neuen psychoaktiven Substanzen und Methamphetamin - Auswertung der Daten aus 6 deutschen Bundesländern

The consumption of new psychoactive substances and methamphetamine—analysis of data from 6 German federal states

Dtsch Arztebl Int 2018; 115(4): 49-55; DOI: 10.3238/arztebl.2018.0049

Gomes de Matos, Elena; Hannemann, Tessa-Virginia; Atzendorf, Josefine; Kraus, Ludwig; Piontek, Daniela


Methamphetamin-bezogene Störungen

Clinical practice guideline: Methamphetamine-related disorders

Dtsch Arztebl Int 2017; 114(26): 455-61; DOI: 10.3238/arztebl.2017.0455

Gouzoulis-Mayfrank, Euphrosyne; Härtel-Petri, Roland; Hamdorf, Willem; Havemann-Reinecke, Ursula; Mühlig, Stephan; Wodarz, Norbert


Misplaced Ecstasy? Questioning the Role of Psychedelics as Therapy

(Medscape, 26.10.2017)


Electronic dance music (EDM) parties have historically been high-risk scenes for use of a variety of psychoactive substances. Studies over the past couple of years have found nightclub and festival attendees report high rates of use. These parties are becoming increasingly popular in the U.S., and drug use at such parties has been associated with severe adverse health outcomes, including death. Severity of potential negative health outcomes in EDM environments makes data on both known and unknown drug use critical to further prevention and harm reduction efforts.


Defending MDMA as a Treatment for PTSD

(Medscape, 11.12.2017)